Merck & Co Inc

Research Merck & Co Inc (MRK) on Bullrun: valuation model: 1.2% overvalued, market cap USD 319.55B, P/E 36.4, dividend yield 2.6%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerMRK
ExchangeNYSE
CountryUnited States
SectorHealthcare
IndustryDrug Manufacturers-General
CurrencyUSD
Valuation signal1.2% overvalued
Market capUSD 319.55B
P/E36.4
Dividend yield2.6%
Financial periodFY2025
RevenueUSD 65.01B
Revenue growth1.3%
Net incomeUSD 18.25B
Free cash flowUSD 12.36B
Gross margin74.8%

Valuation Snapshot

Bullrun's latest valuation model marks Merck & Co Inc as 1.2% overvalued; latest market cap is USD 319.55B; P/E is 36.4; dividend yield is 2.6%.

About Merck & Co Inc

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.

Frequently asked questions

Is Merck & Co Inc overvalued or undervalued?

Bullrun's valuation model currently marks Merck & Co Inc as 1.2% overvalued.

What is Merck & Co Inc's market cap?

Merck & Co Inc's market capitalization is USD 319.55B.

What is Merck & Co Inc's P/E ratio?

Merck & Co Inc's price-to-earnings (P/E) ratio is 36.4.

Does Merck & Co Inc pay a dividend?

Merck & Co Inc has a dividend yield of 2.6%.